In the pivotal ASCENT trial,14 the authors noted a higher rate of grade ≥ 3 SG‐related neutropenia, febrile neutropenia, anemia, and diarrhea in women with the UGT1A1*28/*28 genotype and advised that individuals with the UGT1A1*28/*28 genotype should be monitored closely. This evidence concerns the gene UGT1A1 and anemia (phenotype).